Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: Deviation of thyroid-stimulating to nonfunctional antibodies

Endocrinology

Volumn 150, Issue 8, 2009, Pages 3944-3952

  Misharin, Alexander V ^a   Nagayama, Yuji ^b   Aliesky, Holly A ^a   Mizutori, Yumiko ^a   Rapoport, Basil ^a   McLachlan, Sandra M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAGASAKI UNIVERSITY   (Japan)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN SUBUNIT; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; TSHR 289; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; FEMALE; GLYCOSYLATION; HORMONE ACTION; HORMONE BINDING; HORMONE BLOOD LEVEL; HYPERTHYROIDISM; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; THYROTOXICOSIS;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HYPERTHYROIDISM; IMMUNOGLOBULINS, THYROID-STIMULATING; MICE; MICE, INBRED BALB C; PROTEIN SUBUNITS; RECEPTORS, THYROTROPIN; RECOMBINANT PROTEINS; THYROXINE;

EID: 67651160580     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0181     Document Type: Article

References (44)

1. Rapoport B, McLachlan SM 2007 The thyrotropin receptor in Graves' disease. Thyroid 17:911-922
2. Uibo R, Lernmark A 2008 GAD65 autoimmunity - clinical studies. Adv Immunol 100:39-78
3. Kanta H, Mohan C, Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation. Genes Immun, in press
4. Rowley MJ, Nandakumar KS, Holmdahl R 2008 The role of collagen antibodies in mediating arthritis. Mod Rheumatol 18:429-441
5. Kuerten S, Angelov DN 2008 Comparing the CNS morphology and immunobiology of different EAE models in C57BL/6 mice - a step toward understanding the complexity of multiple sclerosis. Ann Anat 190:1-15
6. Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M 2002 A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 168:2789-2794
7. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM 2003 The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 111:1897-1904
8. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B 2003 Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 170:3522-3527
9. Saitoh O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y 2005 Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor β, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol 141:405-411
10. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B 2004 Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 173:2167-2173
11. Gilbert JA, Kalled SL, Moorhead J, Hess DM, Rennert P, Li Z, Khan MZ, Banga JP 2006 Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with TNF-family ligand inhibitors suggests a key role for BAFF in disease pathology. Endocrinology 147:4561-4568
12. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L 2006 Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16:709-710
13. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P 2007 Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33-40
14. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L 2007 B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92:1769-1772
15. Feldmann M, Steinman L 2005 Design of effective immunotherapy for human autoimmunity. Nature 435:612-619
16. Kita-Furuyama M, Nagayama Y, Pichurin P, McLachlan SM, Rapoport B, Eguchi K 2003 Dendritic cells infected with adenovirus expressing the thyrotropin receptor induce Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol 131:234-240
17. Mizutori Y, Saitoh O, Eguchi K, Nagayama Y 2006 Adenovirus encoding the thyrotropin receptor A-subunit improves the efficacy of dendritic cell-induced Graves' hyperthyroidism in mice. J Autoimmun 26:32-36
18. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC 2001 Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194:769-779
19. Engering AJ, Cella M, Fluitsma D, Brockhaus M, Hoefsmit EC, Lanzavecchia A, Pieters J 1997 The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 27:2417-2425
20. Taylor ME, Conary JT, Lennartz MR, Stahl PD, Drickamer K 1990 Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains. J Biol Chem 265:12156-12162
21. Baumeister FA, Herzog V 1988 Sulfation of thyroglobulin: a ubiquitous modification in vertebrates. Cell Tissue Res 252:349-358
22. Spiro RG, Bhoyroo VD 1988 Occurrence of sulfate in the asparagine-linked complex carbohydrate units of thyroglobulin. Identification and localization of galactose 3-sulfate and N-acetylglucosamine 6-sulfate residues in the human and calf proteins. J Biol Chem 263:14351-14358
23. Linehan SA, Martínez-Pomares L, da Silva RP, Gordon S 2001 Endogenous ligands of carbohydrate recognition domains of the mannose receptor in murine macrophages, endothelial cells and secretory cells; potential relevance to inflammation and immunity. Eur J Immunol 31:1857-1866
24. Chazenbalk GD, Pichurin PN, Guo J, Rapoport B, McLachlan SM 2005 Interactions between the mannose receptor and thyroid autoimmunity. Clin Exp Immunol 139:216-224
25. McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Harris J, Gordon S, Martinez-Pomares L 2007 Mannose receptor expression and function define a new population of murine dendritic cells. J Immunol 178:4975-4983
26. Chazenbalk GD, Wang Y, Guo J, Hutchison JS, Segal D, Jaume JC, McLachlan SM, Rapoport B 1999 A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies. J Clin Endocrinol Metab 84:702-710
27. Chazenbalk GD, McLachlan SM, Pichurin P, Yan XM, Rapoport B 2001 A "prion-like" shift between two conformational forms of a recombinant thyrotropin receptor A subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. J Clin Endocrinol Metab 86:1287-1293
28. Schwarz-Lauer L, Chazenbalk GD, Mclachlan SM, Ochi Y, Nagayama Y, Rapoport B 2002 Evidence for a simplified view of autoantibody interactions with the TSH receptor. Thyroid 12:115-120
29. Guo J, McLachlan SM, Hutchison S, Rapoport B 1998 The greater glycan content of recombinant human thyroid peroxidase of mammalian than on insect cell origin facilitates purification to homogeneity of enzymatically active protein remaining soluble at high concentration. Endocrinology 139:999-1005
30. Pichurin P, Yan XM, Farilla L, Guo J, Chazenbalk GD, Rapoport B, McLachlan SM 2001 Naked thyrotropin receptor DNA vaccination: A TH1 T cell response in which interferon-γ production, rather than antibody, dominates the immune response in mice. Endocrinology 142:3530-3536
31. Chen CR, Aliesky HA, Guo J, Rapoport B, McLachlan SM 2006 Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus. Thyroid 16:427-434
32. Mittereder N, March KL, Trapnell BC 1996 Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509
33. Kakinuma A, Chazenbalk G, Filetti S, McLachlan SM, Rapoport B 1996 Both the 5′ and 3′ non-coding regions of the thyrotropin receptor messenger RNA influence the level of receptor protein expression in transfected mammalian cells. Endocrinology 137:2664-2669
34. Misharin A, Hewison M, Chen CR, Lagishetty V, Aliesky HA, Mizutori Y, Rapoport B, McLachlan SM 2009 Vitamin D deficiency modulates Graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. Endocrinology 150:1051-1060
35. McLachlan SM, Aliesky HA, Pichurin PN, Chen CR, Williams RW, Rapoport B 2008 Shared and unique susceptibility genes in a mouse model of Graves' disease determined in BXH and CXB recombinant inbred mice. Endocrinology 149:2001-2009
36. Lewis M, Giraldo AA, Kong YC 1987 Resistance to experimental autoimmune thyroiditis induced by physiologic manipulation of thyroglobulin level. Clin Immunol Immunopathol 45:92-104
37. Morris GP, Kong YC 2006 Tolerance to autoimmune thyroiditis: (CD4+)CD25+ regulatory T cells influence susceptibility but do not supersede MHC class II restriction. Front Biosci 11:1234-1243
38. Chazenbalk GD, Jaume JC, McLachlan SM, Rapoport B 1997 Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J Biol Chem 272:18959-18965
39. Schwarz-Lauer L, Pichurin PN, Chen CR, Nagayama Y, Paras C, Morris JC, Rapoport B, McLachlan SM 2003 The cysteine-rich amino terminus of the thyrotropin receptor is the immunodominant linear antibody epitope in mice immunized using naked DNA or adenovirus vectors. Endocrinology 144:1718-1725
40. Le TV, Kim TH, Chaplin DD 2008 Intraclonal competition inhibits the formation of high-affinity antibody-secreting cells. J Immunol 181:6027-6037
41. Talbot PJ, Buchmeier MJ 1987 Catabolism of homologous murine monoclonal hybridoma IgG antibodies in mice. Immunology 60:485-489
42. Slifka MK, Antia R, Whitmire JK, Ahmed R 1998 Humoral immunity due to long-lived plasma cells. Immunity 8:363-372
43. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH 2009 Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130:252-258
44. Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, Romijn JA, Smit JW 2008 Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 159:609-615